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Abstract
Background: Single nucleotide polymorphisms (SNPs) in genes involved in the estrogen pathway appear to be
associated with breast cancer risk and possibly with mammographic density (MD), but little is known of these
associations among premenopausal women. This study examines the association of 11 polymorphisms in five
estrogen-related genes (estrogen receptors alpha and beta (ERa,E R b), 17b-hydroxysteroid dehydrogenase 1
(HSD17B1), catechol-O-methyltransferase (COMT), cytochrome P450 1B1 (CYP1B1)) with premenopausal MD. Effect
modification of four estrogen-related factors (parity, age at menarche, hormonal derivatives use and body mass
index (BMI)) on this relation is also assessed.
Methods: Polymorphisms were genotyped in 741 premenopausal Caucasian women whose MD was measured in
absolute density (AD, cm
2) and percent density using a computer-assisted method. Multivariate linear models were
used to examine the associations (Ptrend) and interactions (Pi).
Results: None of the SNPs showed a statistically significant association with AD. However, each additional rare
allele of rs1056836 CYP1B1 was associated with a reduction in AD among nulliparous women (Ptrend = 0.004), while
no association was observed among parous women (Ptrend = 0.62; Pi = 0.02). An increase in the number of rare
alleles of the HSD17B1 SNP (rs598126 and rs2010750) was associated with an increase in AD among women who
never used hormonal derivatives (Ptrend = 0.06 and Ptrend = 0.04, respectively), but with a decrease in AD among
past hormonal derivatives users (Ptrend = 0.04; Pi = 0.02 and Ptrend = 0.08; Pi = 0.01, respectively). Moreover, a
negative association of rs598126 HSD17B1 SNP with AD was observed among women with higher BMI (>median)
(Ptrend = 0.01; Pi = 0.02). A negative association between an increased number of rare alleles of COMT rs4680 SNP
and AD was limited to women who never used hormonal derivatives (Ptrend = 0.02; Pi = 0.03) or with late age at
menarche (>median) (Ptrend = 0.03; Pi = 0.02). No significant association was observed between polymorphisms in
the ERa or ERb genes and AD. Similar results, although less significant, were observed when MD was assessed in
percent density.
Conclusion: SNPs located in CYP1B1, COMT or HSD17B1 genes seem to be associated with MD in some strata of
estrogen-related factors. Our findings suggest that modifying effects of estrogen-related factors should be
considered when evaluating associations of polymorphisms in estrogen-related genes with premenopausal
mammographic density.
Background
There is substantial evidence that steroid hormones
such as estrogens play an important role in the etiology
of breast cancer. In particular, estrogens are believed to
contribute to tumor growth by promoting the prolifera-
tion of cells with existing mutations or perhaps by
increasing the opportunity for mutations [1]. Therefore,
several enzymes and receptors involved in the estrogen
pathway have been suggested to play a role in the devel-
opment of breast cancer [1,2]. Among them, 17b-hydro-
xysteroid dehydrogenase 1 (HSD17B1) is the enzyme
responsible for the conversion of estrone to estradiol [3]
which is the most potent estrogen. Cytochrome P450
1B1 (CYP1B1) catalyses the conversion of estrone and
estradiol to potentially carcinogenic catechol estrogen 4-
hydroxyestrogen (4-OH) [4-6]. The catechol-O-
* Correspondence: caroline.diorio@uresp.ulaval.ca
1Université Laval, Département de médecine sociale et préventive, Quebec
City, QC, Canada
Full list of author information is available at the end of the article
Dumas and Diorio BMC Cancer 2010, 10:636
http://www.biomedcentral.com/1471-2407/10/636
© 2010 Dumas and Diorio; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.methyltransferase (COMT) enzyme is principally
responsible for both the inactivation and detoxification
of catecholestrogens, which can cause oxidative damage
[4,7]. Both estrogen receptors alpha and beta (ERa,
ERb) are members of the nuclear receptor family of
ligand-inducible transcription factors, but they are
believed to have different transcriptional activation
properties [8]. The interaction of estrogen and estrogen
receptors stimulates cell proliferation which is believed
to be one of the mechanisms responsible for the carci-
nogenicity of estrogens in the human breast [1]. Specific
polymorphisms (SNPs) in these estrogen-related genes
could directly or indirectly lead to variations in their
activities and therefore, may have an effect on breast
cancer risk. For instance, certain SNPs located in ERa,
ERb, HSD17B1, COMT and CYP1B1 genes have been
associated with breast cancer risk among premenopausal
or postmenopausal women [9-12] or in some strata of
other estrogen-related factors such as parity, hormone
replacement therapy (HRT) use, age at menarche or
body mass index (BMI) [9,13-15].
Those SNPs located in ERa, ERb, HSD17B1, COMT
and CYP1B1 genes may also be associated to mammo-
graphic density (MD), which is a strong and indepen-
dent risk factor for breast cancer [16]. It has been
repeatedly found that women with 75% or more of MD
have a four to six fold greater risk of developing breast
cancer compared to women with no measurable dense
breast tissue [16,17]. Elevated MD represents a higher
proportion of fibroglandular cells and therefore reflects
a higher proliferative activity within this tissue [18]. The
link between MD and breast cancer is not well under-
stood but it could be related to estrogen. For instance,
in addition to the proliferative effect on fibroglandular
cells of the breast by endogenous or exogenous estro-
gens [1,19], several breast cancer risk factors related to
estrogens such as age, parity, menopausal status or HRT
use, are also associated with MD [16,17]. Because MD is
a highly heritable factor [20], a number of studies exam-
ined the association of SNPs located in estrogen-related
genes with MD [21-33]. In these studies, although no
associations were found among the entire population,
some associations were observed in certain strata of
estrogen-related factors such as menopausal status or
the use of HRT [23,28,29,31,32]. Up to now, few studies
were conducted among premenopausal women [28-33]
and no data is available for stratified analysis based on
estrogen-related factors, even though heritability of MD
has been suggested to be higher in this population [34].
The purpose of this study was to evaluate the relation
between 11 polymorphisms in five genes involved in the
estrogen pathway (ERa, ERb, HSD17B1, COMT and
CYP1B1) and premenopausal MD, and to examine the
modifying effect of four estrogen-related factors (parity,
hormonal derivatives use, age at menarche and BMI) on
these associations.
Methods
Study Population and Recruitment Procedures
Details of the study design and methods have been pub-
lished elsewhere [35]. In summary, subjects participating
in the present study were premenopausal women who
received a screening mammography between February
and December 2001 at the Clinique Radiologique Audet
(Quebec City, QC, Canada). Based on previously pub-
lished criteria [36], to be qualified as premenopausal,
women had to have had at least one menstrual cycle
within previous twelve months, or they had to be
y o u n g e rt h a n4 8y e a r so l df o ran o n s m o k e ro r4 6y e a r s
old for a smoker after hysterectomy without bilateral
oophorectomy. Other restrictions were that women had
to have not taken hormonal derivatives within 3 months
prior to mammography, never have used tamoxifen or
raloxifene, not be pregnant, have no history of cancer at
any site, have had no breast surgery and no endocrine
system disease. Among the 783 premenopausal eligible
women, 37 women did not give authorization for blood
banking of samples for further study. Therefore a total
of 746 women were included in the present study. The
research ethics committee of the CHA universitaire de
Québec (Quebec City, QC, Canada) reviewed and
approved this study. A written informed consent was
provided by all study participants.
Data Collection
Anthropometric measurements and blood samples were
taken at recruitment. Breast cancer risk factors including
reproductive and menstrual history, family history of
breast cancer, personal history of breast biopsies, past
use of hormonal derivatives, smoking status, alcohol
intake, physical activity and education, were documented
by a telephone interview. Diet was assessed with a self-
administered semiquantitative food-frequency question-
naire [37].
Digitization of Mammograms and Assessment of
Mammographic Breast Density
A craniocaudal view of a randomly chosen breast was
evaluated for each women after all mammograms were
digitized using a Kodak Lumiscan85 digitizer at 260 μm
per pixel. The proportion of the breast showing tissue
density (percent density, PD in%) and the absolute
amount of dense tissue (absolute density, AD in cm²)
were assessed by one trained author (C.D.), with a com-
puter-assisted method [38]. The evaluator did not have
any information regarding women’ss t a t u so rm e d i c a l
history. The within-batch intraclass correlation coeffi-
cients (n = 210 duplicate images) were 0.98 and 0.98 for
Dumas and Diorio BMC Cancer 2010, 10:636
http://www.biomedcentral.com/1471-2407/10/636
Page 2 of 10percent and absolute density, respectively. The between-
batch coefficients of variation (n = 10 images repeated
21 times) were 4% for percent density and 5% for abso-
lute density.
DNA Extraction and SNP Genotyping
These procedures were described previously [39]. Briefly,
DNA was extracted from the buffy coat using the
PUREGene DNA extraction kit (Gentra Inc, Minneapo-
lis, MN, USA) following the manufacturer’sp r o t o c o l .
Genomic DNA of five women could not be obtained.
DNA samples were blindly genotyped for 12 SNPs
located in five genes involved in the estrogen pathway:
ERa, ERb, HSD17B1, COMT and CYP1B1.T ob e
included in the present study, SNPs had to be located in
promoter regions or exons, or found to be associated
with breast cancer risk or its associated risk factors in
previous studies [11,40,41]. From the 12 SNPs selected,
11 have been successfully genotyped and described in
Table 1. The SNP not genotyped is rs605059 located in
HSD17B1 gene. SNPs analyses were performed using
the GenomeLab SNPstream (Beckman Coulter) or
Sequenom MassArray (San Diego, Inc.) genotyping plat-
forms according to the manufacturer’s protocols. Each
96-well plate included negative (no DNA) and positive
controls to ensure accuracy of genotyping. Genotyping
call rates for both technologies ranged between 98.2%
and 99.5%. In this study, all genotypes were repeated on
21 blind samples; concordance was 100% for both plat-
forms. Protocols could be provided upon request from
the corresponding author.
Statistical Methods
Deviation from the Hardy-Weinberg equilibrium was
assessed for each SNP by a c2 test with one degree of
freedom, and linkage disequilibrium strength was evalu-
ated with Lewontin’sD ’ statistic for within-gene SNP
pairs. In the present study, no significant deviation from
Hardy-Weinberg expectations was observed for any of
the polymorphisms (P >0 . 0 5 ) ,a n da l lo ft h eD ’ values
were > 0.88 except for pairs of rs2228480 SNP with
others located in ERa (all D’ < 0.19). Generalized linear
models were used to estimate univariate and multivari-
ate-adjusted least-square means of MD by category of
genotypes under codominant mode of inheritance. Lin-
ear regression models were used to evaluate associations
(Ptrend) between the number of copies of the rare allele
entered as a continuous variable (0, 1, 2) and MD. Uni-
variate and multivariate haplotype analyses were done
based on SNPs in region of strong linkage disequili-
brium within gene using the method described by Stram
et al. [42]. For these analyses, the most common haplo-
type was used as the reference category, and rare haplo-
t y p e s( f r e q u e n c y<5 % )w e r ec o m b i n e d .A l lo ft h e
variables met the assumption of normality of residuals
from these analysis with the exception of absolute den-
sity, which was square root transformed and presented
as back-transformed values.
Since the activities of enzymes and receptors related
to the studied genes are regulated by estrogens [43-45],
the modifying effect of four estrogen-related factors on
the associations between genotype and MD was
assessed. These factors are parity (ever/never having a
full-term pregnancy), hormonal derivatives used (ever/
never having used oral contraceptive or hormone repla-
cement therapy), age at menarche (≤ median/> median),
and BMI (≤ median/> median), and they were selected
because they were found as effect modifiers of some
associations between SNPs in estrogen-related genes
and breast cancer risk in previous studies [9,13-15]. An
interaction term between each of these variables and the
genotype dosage was added to the above models. The p-
value of the interaction term (Pi) was used to assess the
effect modification of these variables individually. The
modifying effect of these factors was also evaluated in
haplotype analysis.
Table 1 Single nucleotide polymorphisms evaluated in the present study
Gene name Encoded product N Alleles (major > minor) SNP reference ID
a Gene Location Panel Call Rate
ERa Estrogen receptor a 728 T > C rs2077647 Exon 1 SNPstream 98.2%
735 A > G rs2234693 Intron 1 SNPstream 99.2%
735 A > G rs9340799 Intron 1 SNPstream 99.2%
736 C > T rs2228480 Exon 8 SNPstream 99.3%
ERb Estrogen receptor b 735 T > C rs3829768 Promoter SNPstream 99.2%
737 G > A rs1256049 Exon 6 SNPstream 99.5%
HSD17B1 17b-hydroxysteroid dehydrogenase 1 737 G > T rs676387 Intron 4 Sequenom 99.5%
732 C > T rs598126 COASY : Exon Sequenom 98.8%
734 G > A rs2010750 TCFL4 : Intron Sequenom 99.1%
COMT Catechol-O-methyltransferase 735 G > A rs4680 Exon 4 Sequenom 99.2%
CYP1B1 Cytochrome P450 1B1 737 C > G rs1056836 Exon 3 Sequenom 99.5%
a Polymorphisms are identified by their dbSNP accession number at http://www.ncbi.nlm.nih.gov/SNP/.
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ing age at mammography (years), body mass index (kg/
m
2), waist-to-hip ratio, height (cm), age at menarche
(years), age at first birth (years), number of full-term preg-
nancies, breastfeeding (months), number of breast biop-
sies, family history of breast cancer in first-degree relatives
(yes or no), duration of past contraceptive and hormone
replacement therapy uses (years), smoking status (never,
former or current smoker), energy (Kcal/day) and alcohol
(drinks/week) intakes, physical activity (metabolic equiva-
lent hours/week) and education (completed elementary
school, high school, college or university). Further adjust-
ments were made (season at time of mammography, mul-
tivitamin-multimineral supplement use, phase of the
menstrual cycle at time of mammography, dietary calcium
and vitamin D intakes, plasma insulin-like growth factor-I
and insulin-like growth factor-binding protein-3 levels)
with little or no influence on the estimates. Therefore,
they were not added in the models.
All statistical analyses were performed using the SAS
software package (version 9.2; SAS Institute Inc.). All
tests were 2-sided and a p-value < 0.05 was considered
statistically significant.
Results
Characteristics of the study population are summarized
in Table 2. Of the 741 premenopausal women, 739
reported to be Caucasian (99.7%). The mean age at the
time of mammogram was 46.8 years (standard deviation
(SD) 4.6 years). The mean percent and absolute density
were 42.3% (SD 24.3%) and 47.1 cm
2 (SD 28.7 cm
2)
respectively.
Relation between polymorphisms in genes involved in
the estrogen pathway and MD are presented in Table 3.
Women carrying increased number of copies of the rare
allele of CYP1B1 rs1056836 SNP had decreased adjusted
means of percent (Ptrend = 0.09) and absolute (Ptrend =
0.08) density. However, no SNP in ERa, ERb, HSD17B1,
COMT and CYP1B1 genes was significantly associated
to percent or absolute density (all Ptrend ≥ 0.05). More-
over, we observed no significant association of any hap-
lotypes within ERa or HSD17B1 genes with percent or
absolute density (data not shown).
Table 4 presents the effect modification of parity, hor-
monal derivatives used, age at menarche and BMI found
statistically significant on the relation between poly-
morphisms in estrogen-related genes and MD. The
results from these analyses regardless of statistical signif-
icance are detailed in Additional files 1, 2, 3 and 4.
Among nulliparous women, an increase of rare alleles of
CYP1B1 rs1056836 SNP was negatively associated with
AD (Ptrend = 0.004), while no association was observed
among parous women (Ptrend = 0.62; Pi = 0.02). Effect
modification of parity on the association between
COMT rs4680 SNP and AD was also observed (Pi <
0.05), but no association reached statistical significance
among nulliparous (Ptrend =0 . 1 5 )o rp a r o u s( Ptrend =
0.12) women. We found that an increase in the number
of rare alleles of the HSD17B1 SNP (rs598126 and
rs2010750) was associated with a decrease in AD among
women who ever used hormonal derivatives (Ptrend =
0.04 and Ptrend = 0.08, respectively), but with an increase
in AD among women who never used them (Ptrend =
0.06; Pi =0 . 0 2a n dPtrend =0 . 0 4 ;Pi = 0.01, respectively).
Moreover, among women who never used hormonal
derivatives, an increase in the number of rare alleles of
the COMT rs4680 SNP was found to be negatively asso-
ciated with AD (Ptrend =0 . 0 2 ;Pi = 0.03). These associa-
tions and effect modifications remain similar when the
analysis is limited to women who ever or never used
oral contraceptive (data not shown). Effect modification
of age at menarche on the association of COMT rs4680
SNP with AD was also observed (Pi = 0.02), revealing a
negative association between an increase of rare alleles
of this genotype and AD limited to women with an age
at menarche above the median value (Ptrend =0 . 0 3 ) .
Among women with a BMI above the median value, an
increase in the number of rare alleles of the HSD17B1
rs598126 SNP was associated with a decrease in AD
(Ptrend = 0.01), while no association was observed
among those with a BMI below or equal to the median
Table 2 Characteristics of study subjects (N = 741)
Characteristic Mean SD
Age at mammography (years) 46.8 4.6
Body mass index (kg/m
2) 25.2 4.6
Waist-to-hip ratio 0.8 0.1
Height (cm) 160.5 5.8
Age at menarche (years) 12.7 1.6
Age at first pregnancy (years)
a (n = 563) 26.0 3.7
Number of live births
a (n = 563) 2.1 0.8
Alcohol intake (drinks/wk) (n = 738) 3.4 3.8
Total energy intake (Kcal/day) (n = 736) 1906.0 514.9
Physical activity (MET-h/wk) (n = 740) 27.1 22.2
Percent density (%) 42.3 24.3
Absolute density (cm²) 47.1 28.7
%
Parity (parous) 76.0
Lactation (yes)
a (n = 563) 62.0
Personal history of breast biopsies (yes) 14.2
Past hormonal derivative use (yes) (n = 740)
b 92.4
First degree relative with breast cancer (yes) 36.8
Education (college or university degree) 62.0
Smoking status (never) 45.1
a Among parous women
b Past oral contraceptive (92.2%) and hormone replacement therapy (6.1%)
uses
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Page 4 of 10Table 3 Associations between SNPs in genes involved in the estrogen pathway and mammographic density
Mean mammographic density
Percent density (%) (95% CI)
a Absolute density (cm
2)
b (95% CI)
Gene name SNP reference ID
c Genotype N (%)
d Crude Adjusted
e Crude Adjusted
e
ERa rs2077647 TT 189 (25.96) 42.5 (39.0-46.0) 42.5 (39.7-45.4) 47.7 (43.6-51.9) 47.6 (43.8-51.7)
TC 357 (49.04) 42.5 (40.0-45.1) 42.5 (40.5-44.6) 47.8 (44.8-50.8) 47.1 (44.3-50.0)
CC 182 (25.00) 42.6 (39.0-46.1) 43.3 (40.4-46.3) 45.5 (41.5-49.7) 44.8 (40.9-48.8)
Ptrend
f 0.98 0.69 0.48 0.31
rs2234693 AA 211 (28.71) 41.6 (38.3-44.8) 42.3 (39.5-45.0) 48.0 (44.1-52.0) 48.3 (44.6-52.2)
AG 350 (47.62) 42.6 (40.1-45.2) 42.1 (40.0-44.2) 47.6 (44.7-50.7) 46.7 (43.9-49.7)
GG 174 (23.67) 42.7 (39.1-46.3) 43.7 (40.7-46.7) 45.2 (41.1-49.4) 44.3 (40.4-48.4)
Ptrend 0.63 0.50 0.35 0.16
rs9340799 AA 301 (40.95) 42.1 (39.3-44.8) 42.7 (40.5-45.0) 49.1 (45.8-52.5) 49.4 (46.2-52.6)
AG 327 (44.49) 42.2 (39.6-44.9) 41.8 (39.6-43.9) 45.8 (42.8-49.0) 44.6 (41.7-47.5)
GG 107 (14.56) 43.9 (39.3-48.5) 44.9 (41.1-48.7) 46.6 (41.4-52.2) 46.2 (41.2-51.6)
Ptrend 0.58 0.58 0.26 0.11
rs2228480 CC 508 (69.02) 41.5 (39.4-43.6) 42.0 (40.3-43.8) 46.3 (43.9-48.9) 46.1 (43.8-48.5)
CT 207 (28.13) 44.4 (41.1-47.7) 43.4 (40.7-46.1) 48.6 (44.7-52.6) 46.9 (43.2-50.8)
TT 21 (2.85) 43.0 (32.6-53.4) 47.3 (38.7-55.9) 53.2 (40.9-67.2) 56.6 (44.3-70.5)
Ptrend 0.20 0.20 0.19 0.25
ERb rs3829768 TT 733 (99.73) 42.4 (40.6-44.1) 42.6 (41.2-44.0) 47.2 (45.1-49.3) 46.7 (44.7-48.7)
TC 2(0.27) 30.3 (-3.4-64.0) 16.5 (-11.2-44.2) 45.6 (15.9-94.2) 34.0 (10.6-74.7)
Ptrend 0.48 0.07 0.94 0.48
rs1256049 GG 688 (93.35) 42.6 (40.8-44.4) 42.8 (41.3-44.2) 47.4 (45.3-49.6) 46.9 (44.8-48.9)
GA 48 (6.51) 38.9 (32.0-45.8) 40.0 (34.3-45.6) 44.2 (36.7-52.4) 44.5 (37.3-52.5)
AA 1 (0.14) 43.0 (-4.7-90.7) 54.1 (12.1-133.8)
Ptrend 0.33 0.35 0.50 0.57
HSD17B1 rs676387 GG 390 (52.92) 42.2 (39.8-44.6) 41.7 (39.8-43.7) 46.2 (43.4-49.0) 45.1 (42.5-47.8)
GT 288 (39.08) 42.8 (40.0-45.6) 43.4 (41.1-45.7) 48.4 (45.1-51.8) 48.4 (45.2-51.7)
TT 59 (8.01) 40.1 (33.9-46.3) 42.6 (37.4-47.9) 46.4 (39.5-54.0) 47.3 (40.4-54.8)
Ptrend 0.83 0.39 0.53 0.20
rs598126 CC 195 (26.64) 41.2 (37.8-44.7) 42.6 (39.8-45.5) 48.2 (44.2-52.4) 48.4 (44.5-52.5)
CT 354 (48.36) 43.7 (41.1-46.2) 43.1 (41.0-45.2) 47.6 (44.6-50.6) 46.6 (43.8-49.5)
TT 183 (25.00) 40.5 (37.0-44.1) 41.0 (38.1-43.9) 44.5 (40.6-48.6) 44.3 (40.5-48.3)
Ptrend 0.81 0.44 0.21 0.15
rs2010750 GG 237 (32.29) 41.9 (38.8-45.0) 42.8 (40.3-45.4) 47.7 (44.1-51.5) 47.5 (44.0-51.1)
GA 351 (47.82) 43.6 (41.0-46.1) 43.1 (41.0-45.1) 48.0 (45.0-51.1) 47.3 (44.5-50.2)
AA 146 (19.89) 40.2 (36.3-44.2) 41.0 (37.7-44.2) 44.2 (39.9-48.8) 44.0 (39.7-48.4)
Ptrend 0.67 0.46 0.30 0.26
COMT rs4680 GG 190 (25.85) 43.1 (39.6-46.6) 42.4 (39.5-45.3) 48.0 (44.0-52.2) 47.7 (43.8-51.8)
GA 375 (51.02) 43.3 (40.8-45.8) 43.8 (41.7-45.8) 47.1 (44.3-50.1) 46.5 (43.7-49.3)
AA 170 (23.13) 39.0 (35.3-42.6) 39.6 (36.6-42.6) 45.7 (41.6-50.1) 45.4 (41.5-49.6)
Ptrend 0.12 0.21 0.45 0.43
CYP1B1 rs1056836 CC 219 (29.72) 43.7 (40.4-46.9) 43.7 (41.0-46.3) 49.6 (45.8-53.6) 48.8 (45.2-52.6)
CG 372 (50.47) 42.3 (39.8-44.8) 42.8 (40.8-44.8) 46.7 (43.8-49.6) 46.4 (43.7-49.2)
GG 146 (19.81) 40.2 (36.2-44.1) 39.8 (36.6-43.1) 44.2 (39.9-48.9) 43.6 (39.4-48.0)
Ptrend 0.18 0.09 0.07 0.08
a CI: confidence interval.
b Means of absolute density are presented as back-transformed values.
c SNPs: single nucleotide polymorphisms. They are identified by their dbSNP accession number at http://www.ncbi.nlm.nih.gov/SNP/.
d N (%) values are slightly lower in adjusted models because of ten missing values in adjustment variables.
e Adjusted for age at mammography, body mass
index, waist-to-hip ratio, height, age at menarche, age at first birth, number of full-term pregnancies, breastfeeding, number of breast biopsies, family history of
breast cancer, past contraceptive and hormone replacement therapy uses, smoking status, energy and alcohol intakes, physical activity and education.
f P value is
the P trend, testing genotype dosage, number of copies of the rare allele entered as 0, 1, 2 and mammographic density entered as continuous variable.
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Page 5 of 10Table 4 Modifying effect of estrogen-related factors on the association between SNPs and mammographic density
SNP reference Adjusted mean mammographic density (95% CI)
a
Gene name ID
b Genotype N (%) Percent density (%) Absolute density (cm
2)
c
Parity: No Yes No Yes No Yes
COMT rs4680 GG 44 (6.1) 143 (19.7) 43.1 (37.1-49.1) 42.0 (38.7-45.3) 43.3 (35.7-51.7) 48.8 (44.3-53.6)
GA 96 (13.2) 275 (38.0) 45.3 (41.3-49.3) 43.3 (41.0-45.7) 46.4 (41.1-52.1) 46.7 (43.5-50.1)
AA 34 (4.7) 133 (18.3) 43.4 (36.7-50.0) 38.6 (35.2-42.0) 52.6 (43.3-62.9) 43.6 (39.3-48.2)
Ptrend
d 0.93 0.17 0.15 0.12
Pi
e 0.47 0.05
CYP1B1 rs1056836 CC 53 (7.3) 163 (22.4) 46.6 (41.1-52.1) 42.8 (39.7-45.8) 54.2 (46.4-62.7) 47.2 (43.1-51.5)
GC 86 (11.8) 282 (38.8) 46.3 (42.0-50.5) 41.8 (39.5-44.1) 47.0 (41.3-53.0) 46.4 (43.3-49.6)
GG 35 (4.8) 108 (14.8) 36.9 (30.3-43.5) 40.6 (36.8-44.3) 37.0 (29.5-45.4) 45.5 (40.6-50.7)
Ptrend 0.04 0.38 0.004 0.62
Pi 0.19 0.02
Hormonal derivatives used: No Yes No Yes No Yes
HSD17B1 rs598126 CC 14 (1.9) 177 (24.5) 38.3 (27.7-49.0) 43.0 (40.1-45.9) 38.1 (26.3-52.4) 49.3 (45.2-53.5)
CT 24 (3.3) 326 (45.2) 44.2 (36.2-52.2) 43.0 (40.9-45.2) 45.4 (35.2-56.9) 46.6 (43.7-49.7)
TT 16 (2.2) 165 (22.9) 52.0 (42.1-61.8) 39.9 (36.9-42.9) 56.6 (42.6-72.7) 43.1 (39.2-47.2)
Ptrend 0.06 0.16 0.06 0.04
Pi 0.03 0.02
HSD17B1 rs2010750 GG 15 (2.1) 218 (30.1) 38.2 (27.9-48.5) 43.1 (40.5-45.8) 37.9 (26.5-51.7) 48.2 (44.6-52.0)
AG 25 (3.5) 322 (44.5) 44.7 (36.8-52.5) 42.9 (40.8-45.1) 45.8 (35.8-57.2) 47.4 (44.4-50.4)
AA 15 (2.1) 129 (17.8) 52.9 (42.8-63.0) 39.6 (36.2-43.0) 58.7 (44.1-75.7) 42.4 (38.0-47.0)
Ptrend 0.04 0.16 0.04 0.08
Pi 0.02 0.01
COMT rs4680 GG 15 (2.1) 172 (23.7) 47.5 (37.3-57.6) 41.8 (38.9-44.8) 55.0 (40.9-71.4) 47.0 (43.0-51.2)
GA 29 (4.0) 342 (47.1) 49.1 (41.7-56.6) 43.3 (41.2-45.4) 50.2 (40.2-61.5) 46.1 (43.3-49.0)
AA 11 (1.5) 156 (21.5) 31.8 (20.1-43.6) 40.2 (37.1-43.3) 30.6 (19.4-44.9) 46.6 (42.5-51.0)
Ptrend 0.07 0.50 0.02 0.93
Pi 0.12 0.03
Age at menarche (median) (years): ≤12 > 12 ≤12 > 12 ≤12 > 12
COMT rs4680 GG 76 (10.8) 108 (15.3) 41.2 (36.7-45.6) 43.7 (39.9-47.5) 42.7 (37.0-48.8) 51.6 (46.2-57.2)
GA 165 (23.3) 196 (27.7) 43.0 (40.0-46.1) 43.9 (41.1-46.7) 48.7 (44.5-53.1) 43.7 (40.1-47.5)
AA 73 (10.3) 89 (12.6) 40.8 (36.2-45.4) 38.2 (34.1-42.4) 47.9 (41.7-54.6) 43.4 (38.1-49.0)
Ptrend 0.93 0.06 0.22 0.03
Pi 0.25 0.02
Body mass index (median) (kg/m
2): ≤24.4 > 24.4 ≤24.4 > 24.4 ≤24.4 > 24.4
HSD17B1 rs598126 CC 91 (12.6) 100 (13.9) 49.8 (45.5-54.1) 34.5 (30.4-38.6) 49.1 (43.3-55.2) 47.1 (41.7-52.9)
CT 188 (26.0) 162 (22.4) 51.3 (48.3-54.3) 34.7 (31.5-38.0) 50.0 (45.8-54.3) 43.7 (39.5-48.0)
TT 92 (12.7) 89 (12.3) 52.3 (48.0-56.6) 29.1 (24.7-33.4) 51.9 (45.9-58.2) 37.2 (32.2-42.6)
Ptrend 0.42 0.08 0.53 0.01
Pi 0.07 0.02
a Analyses are adjusted for age at mammography, body mass index, waist-to-hip ratio, height, age at menarche, number of breast biopsies, family historyo f
breast cancer, past contraceptive and hormone replacement therapy uses, smoking status, energy and alcohol intakes, physical activity and education when
applicable. Except for modifying effect of parity, models were also adjusted for age at first birth, number of full-term pregnancies and breastfeeding. CI:
confidence interval.
b SNPs: single nucleotide polymorphisms. They are identified by their dbSNP accession number at http://www.ncbi.nlm.nih.gov/SNP/.
c Means of absolute density are presented as back-transformed values.
d P value is the P trend, testing genotype dosage, number of copies of the rare allele entered as 0, 1, 2 and mammographic density entered as a continuous
variable.
e P value for interaction between the variable (parity, hormonal derivative used, age at menarche or body mass index) and the genotype dosage from linear
regression.
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was used as the dependent variable, similar trends were
observed but they were less statistically significant. No
significant effect modification of estrogen-related factors
on the association of haplotypes within ERa or
HSD17B1 genes with percent or absolute MD was
observed (data not shown).
Discussion
In the present study, we evaluated the association of 11
polymorphisms in five genes involved in the estrogen
pathway with MD, and found no overall association in
premenopausal women. However, some SNPs located in
the CYP1B1, COMT or HSD17B1 genes were found to
be associated with MD among nulliparous women, non-
hormonal users, those with late menarche or among
women with high BMI. These results highlight the need
to consider the modifying effect of estrogen-related fac-
tors when evaluating associations of SNPs involved in
the estrogen pathway with MD.
Although no overall association was found between
three SNPs (rs598126, rs2010750 and rs676387 in strong
linkage disequilibrium) in the HSD17B1 gene and MD,
we found some associations within strata of BMI and
hormonal derivatives used. We observed a decrease in
MD with an increasing number of the rare allele of
rs598126 SNP among women with higher BMI or past
hormonal derivatives users. In contrast, among women
who never used hormonal derivatives, MD increased by
about 20 cm² or 14% for women who are homozygote
for the rare allele (TT for rs598126 or AA for
rs2010750) compared to women homozygote for the
common allele (CC or GG respectively), and this asso-
ciation was borderline or statistically significant even
with a restricted number of women in this stratum. To
our knowledge, these SNPs have not been investigated
in relation with MD. However, Feigelson et al. who
reported no evidence of an association between
HSD17B1 rs598126 or rs2010750 SNP and overall risk
of breast cancer, found that, among tumors that were
negative for the estrogen receptors (ER), additional copy
of rare alleles was associated with an increased risk of
breast cancer [41]. It has been suggested that ER-nega-
tive tumors have less estrogenic activity demonstrated
by lower levels of estrogen as compared to ER-positive
tumors [46]. Since women who never used hormonal
derivatives are believed to have less estrogenic activity
than women using them [47], results from Feigelson
and colleagues on breast cancer risk seem consistent
with ours on MD. Little is known about the biology of
SNPs in HSD17B1 gene, therefore these associations
need to be confirmed in further studies.
The evaluation of the relation between CYP1B1
rs1056836 SNP and MD did not show a significant
association in our overall population of premenopausal
women which is consistent with other studies conducted
in premenopausal [28,32,33] as well as in postmenopau-
sal [21,22,28] women. However, we observed that,
among nulliparous women, carriers of increasing num-
ber of G (Val) allele of CYP1B1 gene have lower MD.
Since nulliparous women have been related to higher
estrogenic activity then parous women [48], our results
suggest that an increasing number of the Val allele is
related to lower MD among women presenting higher
estrogenic activity. Although this is the first study to
find such association among nulliparous women, Lord
et al. observed a similar one among another group of
women presenting higher estrogenic activity; postmeno-
pausal hormone (PMH) users [23]. Using data from
clinical trials, they reported that among women that
used combined estrogen and progesterone for the pre-
vious year, the increase in MD was lower for women
carrying Val/Val genotype than those carrying Leu/Leu
genotype [23]. However, no interaction between
CYP1B1 rs1056836 SNP and PMH status (current users
vs. never or past use) was reported in the cross-sectional
study conducted by Haiman et al. [28]. The fact that the
activity of the CYP1B1 enzyme is regulated by estrogen
may explain why associations of CYP1B1 rs1056836
SNP with MD are observed among women presenting
higher estrogenic activity. However the biological effect
of this polymorphism is still unclear. Data from labora-
tory studies suggest that the Leu allele might have an
increased action in the activation of mammary procarci-
nogens [49] known to stimulate cell proliferation
[50,51]. Conversely, the substitution of leucine to valine
in position 432 of the CYP1B1 enzyme has been related
to a higher production of 4-OH, increasing the 4-OH/2-
OH ratio which could lead to higher mitogenic stimula-
tion of breast cells [49].
Among studies that examined the relation of SNP
rs4680 in the COMT gene with MD, most of them
[22,23,28-31], although not all [31,32], found no associa-
tion among premenopausal [28-30] or postmenopausal
[22,23,28,30,31] women. However, two studies con-
ducted in multiethnic premenopausal women suggested
that MD decreased with each additional copy of the A
(Met) allele [31,32]. Our findings support a similar asso-
ciation but only among women that had lower estro-
g e n i ca c t i v i t yl i k ea m o n gt h o s ew h on e v e ru s e d
hormonal derivatives or had a late menarche [47,52]. To
our knowledge no other study evaluated the possible
modifying effect of age at menarche, but three examined
the modifying effect of PMH use on the relation
between COMT rs4680 SNP and MD [23,28,29]. In one
study, Haiman and colleagues reported that an increase
in the Met allele was associated with a decrease in MD
among never and past PMH users, while no association
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Page 7 of 10was observed among current users [28]. In another
s t u d yc o n d u c t e db yt h es a m eg r o u p ,a ni n c r e a s eo fA
(Met) alleles was associated to an increase in MD for
current PMH users, and no association was found for
never and past users [29]. However, data from a clinical
trial showed no association within strata of different
PMH uses (estrogen or combined estrogen and proges-
terone) [23]. Estrogen is known to down-regulate the
activity of the COMT enzyme [44] which inactivates by
O-methylation the catechol metabolite of estrogen 4-
OH. The variant allele of the gene coding for COMT,
the Met allele, has been associated to lower enzymatic
activity [53,54]. Therefore, the Met allele should be
associated with an increased proliferative activity,
because of less inactivation of 4-OH in presence of
estrogen. It would be biologically reasonable to presume
that additional copies of the Met allele would be asso-
ciated with an increase in MD, particularly among
women with increased estrogenic activity. Up to now,
observations from our group and others suggest an
increase in MD with additionalc o p i e so ft h eM e ta l l e l e
among women with higher estrogenic activity (hormonal
derivatives users) or a decrease in MD with additional
copies of the Met allele among women with lower estro-
genic activity (late age at menarche or those who never
hormonal derivatives) [28,29].
We evaluated the relation of SNPs in ERa or ERb
gene with MD among premenopausal women only, and
our results showed no significant association or effect
modification by estrogen-related factors. Up to now, the
association between SNPs in ER genes and MD has
been inconsistent [22,24,26,27,33]. Crandall et al. found
no association between SNP rs9340799 (ERa)o r
rs1256049 (ERb)a n dM Da m o n gp r e m e n o p a u s a l
w o m e nb u tt h eg e n o t y p eh o m o z y g o t ef o rt h er a r ea l l e l e
of SNP rs2234693 (ERa) was related to a higher MD
[33]. Among a population composed of premenopausal
and postmenopausal women, MD was not related to
ERa rs2234693 SNP but it had a negative association
with the rare allele of rs9340799 SNP [26]. Among post-
menopausal women, no association was found for ERa
rs2234693 [22] or rs2077647 [24] SNP and MD, but the
rare allele of rs9340799 SNP was related to a higher
MD [24].
This study has some limitations. We cannot exclude
that our findings may be due to chance because we eval-
uated several associations. Type I errors or false-positive
results are therefore possible. Population stratification
can be a concern in this type of study [55,56]. However,
it might not be a problem here because our population
was mostly composed (99.7%) of Caucasian women and
of over 87.7% French-Canadians [39]. Non-differential
misclassification bias from genotyping measurements is
possible although it is unlikely in the absence of Hardy-
Weinberg disequilibrium and complete concordance for
repeated samples. Non-differential misclassification of
MD is also possible. However, if present, it should be
relatively small and most likely random because all of
the mammograms were performed at the same clinic
and MD was assessed blindly by one observer whose
reliability of reading was shown to be high.
Conclusion
This study proposes that some SNPs located in the
CYP1B1, COMT or HSD17B1 genes are associated with
MD among nulliparous women, non-hormonal users,
t h o s ew i t hl a t em e n a r c h eo ra m o n gw o m e nw i t hh i g h
BMI. Our findings suggest that modifying effects of
estrogen-related factors should be considered when eval-
uating associations of polymorphisms in estrogen-related
genes with premenopausal mammographic density.
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